Praful Ravi
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Praful Ravi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:22 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06964958 · 177LuPSMA in Renal Cell CarcinomaDana-Farber Cancer Institute · active not recruiting · Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer · principal investigator
- Ph1NCT06303713 · LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate CancerDana-Farber Cancer Institute · active not recruiting · Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph1NCT05617885 · Neo-DAB: Darolutamide and Abemaciclib in Prostate CancerPraful Ravi, MB BCHir, MRCP · terminated · Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 18:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- DF/HCC Prostate SPOREP50CA272390 · NCI · DANA-FARBER CANCER INST · PI Steven P. Balk, Himisha Beltran · fiscal years 2023 to 2026Named on NCT05617885
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 18:22 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.Ann Oncol · 202483 citationsRCR 9.5
- 25 citationsRCR 0.6
- Comparison of the efficacy of venous coupler and hand-sewn anastomosis in maxillofacial reconstruction using microvascular fibula free flaps: a prospective randomized controlled trial.Int J Oral Maxillofac Surg · 201817 citationsRCR 2.1
- Is the Vazirani-Akinosi Nerve Block a Better Technique Than the Conventional Inferior Alveolar Nerve Block for Beginners?J Oral Maxillofac Surg · 201913 citationsRCR 1.7
- Ketamine and the oculocardiac reflex. Dysrhythmia in pediatric strabismus surgery: the role of intravenous atropine.Anaesthesia · 19769 citationsRCR 0.8
- IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer.Endocr Relat Cancer · 20238 citationsRCR 0.8
- Evaluation of internal dose to members of the public at the Kaiga site, India, due to the ingestion of primordial radionuclide 40K.Radiat Prot Dosimetry · 20131 citationsRCR 0.1
- Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.Clin Genitourin Cancer · 2026